Table 1.
Patient demographics and baseline characteristics
| Characteristic | Value (N = 80) |
|---|---|
| Median age, years (range) | 60.0 (34–84) |
| Sex, n (%) | |
| Male | 63 (79) |
| Female | 17 (21) |
| Race | |
| White, n (%) | 72 (90) |
| Black, n (%) | 1 (1) |
| Asian, n (%) | 1 (1) |
| Other | 3 (4) |
| Information missing | 3 (4) |
| Ethnicity | |
| Hispanic or Latino | 5 (6) |
| Not Hispanic or Latino | 67 (84) |
| Not stated | 2 (3) |
| Unknown | 6 (8) |
| Variant HCL, n (%) | 3 (4) |
| Splenectomy, n (%) | 5 (6) |
| Number of prior systemic therapies, median (range) | 3 (2–11) |
| > 3 prior lines, n (%) | 39 (49) |
| Baseline hemoglobin, g/dL, median (range) | 11.1 (6.5–16.3) |
| Baseline neutrophil count, × 103/µL, median (range) | 0.81 (0.1–6.2) |
| Baseline platelet count, × 103/µL, median (range) | 68.0 (6.0–350.0) |
| Prior cancer therapy, n (%) | |
| PNA | 80 (100) |
| Rituximab | 60 (75) |
| BRAF inhibitor | 14 (18) |
| Interferon-α | 20 (25) |
| Other | 8 (10) |
| Unfit for PNA re-treatment, n (%) | 30 (38) |
| At risk of infectiona | 20 (25) |
| Active infectionb | 19 (24) |
| Patients refractory to PNA,c n (%) | 39 (49) |
| PNA monotherapyd | 29 (36) |
| PNA + rituximabe | 15 (19) |
HCL hairy cell leukemia, OR overall response, PNA purine nucleoside analog
aPatients whose baseline absolute neutrophil count was < 0.5 × 103/µL
bPatients whose medical history included a serious infection or febrile neutropenia marked as ‘ongoing’ or ending after the first dose of moxetumomab
cPatients whose HCL was refractory to any line of PNA. Note: A patient was counted as having HCL refractory to PNA monotherapy and/or PNA + rituximab
dPatients who did not achieve an OR or who achieved an OR lasting < 1 year
ePatients who did not achieve an OR or who achieved an OR lasting < 2 years